Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.US-based biotech firm Avalon GloboCare has collaborated with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria to develop an S-layer vaccine against Covid-19 for intranasal or oral administration.
The partners are working to develop a vaccine candidate that would trigger an immune response sufficient to prevent a severe form of Covid-19 infection, which is responsible for morbidity and can lead to death.
Avalon GloboCare noted that the vaccine candidate is a fusion of an S-layer viral particle mimic and the SARS-CoV-2 spike protein.